Subscribe to Newsletter

Business & Regulation


Business & Regulation Business Practice

This Week’s Biopharma News: Pfizer and Astellas Drug Improves Cancer Survival

| Rob Coker | 4 min read

Our latest news roundup reports on a new blow for Harvard, how Pfizer and Astellas’ Xtandi improves cancer survival, and more.

Business & Regulation Business Practice

Behind the Scenes of a GMP Win

| 4 min read

We ask a company about lessons learned from the GMP certification process.

Business & Regulation Business Practice

The New Age of Global, Political, and Regulatory Challenges

| 7 min read

A report attempts to unravel the many challenges that face business leaders. We discuss those inherent in the pharmaceutical industry.

Business & Regulation Business Practice

What Trump’s Latest Moves Mean for the Industry

| 6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”

Business & Regulation Standards & Regulation

This Week’s Industry News: Changes at the top of Novo Nordisk

| 3 min read

Our latest news roundup reports on changes at Novo Nordisk, AbbVie’s ADC accelerated approval, Regeneron’s new acquisition, and more.

Business & Regulation Business Practice

The Challenges and Successes of A Biotech Startup

| Dan Williams | 3 min read

Discussing the challenges facing small rare disease-focussed biotechs, and the successes of advancing treatments.

Business & Regulation Profession

Life Through A Scientific Lens

| 6 min read

From academia in Milan to professional development in the UK, Valo Therapeutics CEO Marcella Origgi shares her journey.

Business & Regulation Bioprocessing - Upstream & Downstream

The Power List Personified: Getting to Know Beatrice Lavery

| Rob Coker | 4 min read

Now that the 2025 Power List is live, we speak with the people working hard every day to make a difference.

Business & Regulation Advanced Medicine

This Week’s Biopharma News: Long-Running CRISPR Patent Case Reopened

| Rob Coker | 4 min read

Our latest roundup reports on Trump's “most favored nation” order, an EMA investigation into finasteride, and Novo Nordisk’s continued R&D for obesity

Business & Regulation Standards & Regulation

The Trump Effect on Biopharma: FDA Disruption, Tariffs, and Funding Cuts

| 5 min read

Trump continues to send shockwaves through the industry. We look at FDA disruption, tariffs, funding volatility, and more.


Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

May Issue of The Medicine Maker